Pharmacotherapy of resistant arterial hypertension


Cite item

Full Text

Abstract

Pharmacotherapy of resistant arterial hypertension represents a serious problem, because today there are no clear algorithms of action in this clinical situation. The review discusses the key works in which the authors propose a solution to this problem. The variants of a differentiated approach to treatment based on hemodynamic type, plasma renin activity, as well as a number of empirical strategies, including the predominant use of mineralocorticoid receptor antagonists, are discussed.

About the authors

N E Shepeleva

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

врач-терапевт лечебно-диагностического отделения Университетской клинической больницы №1 Moscow, Russia

A V Rodionov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

врач-кардиолог лечебно-диагностического отделения Университетской клинической больницы №1 Moscow, Russia

V V Fomin

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: fomin_vic@mail.ru
член-корр. РАН, проректор по научно-исследовательской и лечебной работе, д.м.н., проф. каф. внутренних, профессиональных болезней и пульмонологии медико-профилактического факультета Moscow, Russia

References

  1. Lim S.S, Vos T, Flaxman A.D, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2224-60. doi: 10.1016/S0140-6736(12)61766-8
  2. Daugherty S.L, Powers J.D, Magid D.J, Tavel H.M, Masoudi F.A, Margolis K.L, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42. doi: 10.1161/ CIRCULATIONAHA.111.068064
  3. Smith S.M, Gong Y, Handberg E, Messerli F.H, Bakris G.L, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635-43. doi: 10.1097/HJH.0000000000000051
  4. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80. doi: 10.1161/HYPERTENSIONAHA.111.170308
  5. De la Sierra A, Segura J, Banegas J.R, Gorostidi M, Juan J, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classifi ed on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902. doi: 10.1161/HYPERTENSIONAHA.110.168948
  6. Sim J.J, Bhandari S.K, Shi J, Liu ILA, Calhoun D.A, Mc Glynn E.A, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Elsevier; 2013. P. 1099-107.
  7. Achelrod D, Wenzel U, Frey S. Systematic review and meta - analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355-61. doi: 10.1093/ajh/ hpu151
  8. Garg J.P, Elliott W.J, Folker A, Izhar M, Black H.R. RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university - based cohorts. Am J Hypertens. 2005;18(5, Pt. 1):619-26. doi: 10.1016/j.amjhyper.2004.11.021
  9. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. doi: 10.1093/eurheartj/eht151
  10. Krause T, Lovibond K, Caulfield M, Mc Cormack T, Williams B. Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;25:343:d4891.
  11. Whelton P.K, Carey R.M, Aronow W.S, Casey D.E. Jr, Collins K.J, Dennison Himmelfarb C, De Palma S.M, Gidding S, Jamerson K.A, Jones D.W, Mac Laughlin E.J, Muntner P, Ovbiagele B, Smith S.C. Jr, Spencer C.C, Stafford R.S, Taler S.J, Thomas R.J, Williams K.A. Sr, Williamson J.D, Wright J.T. Jr. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 Nov 13.
  12. Moser M, Setaro J.F. Clinical practice. Resistant or difficult - to - control hypertension. N Engl J Med. 2006 Jul 27;355(4):385-92. doi: 10.1056/NEJMcp041698
  13. Chazova I, Schlaich M.P. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Intern J Hypertens. 2013;2013:541689. doi: 10.1155/2013/541689
  14. Taler S, Textor S, Augustine J. Resistant hypertension. Comparing hemodynamic management to specialist care. Hypertension. 2002;39:982-8. doi: 10.1161/01.HYP.0000016176.16042.2F
  15. Hirsch S. A different approach to resistant hypertension. Cleve Clin J Med. 2007 Jun;74(6):449-56. doi: 10.3949/ccjm.74.6.449
  16. Graves J, Bloomfield R, Buckalew V. Plasma volume in resistant hypertension: Guide to pathophysiology and therapy. Am J Med Sci. 1989;298:361-5. doi: 10.1097/00000441-198912000-00001
  17. Ramsey L, Silas J, Freestone S. Diuretic treatment of resistant hypertension. BMJ. 1980;281:1101-3. doi: 10.1136/bmj.281.6248.1101
  18. Mann S.J. Drug therapy for resistant hypertension: a simplified, mechanistic approach. J Clin Hypertens (Greenwich). 2011;13:120-30. doi: 10.1111/j.1751-7176.2010.00387.x
  19. Mann S.J, Parikh N.S. A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. J Clin Hypertens (Greenwich). 2012;14:191-7. doi: 10.1111/j.1751-7176.2012. 00605.x
  20. Egan B.M, Basile J.N, Rehman S.U, et al. Plasma Renin Test - Guided Drug Treatment Algorithm for Correcting Patients With Treated but Uncontrolled Hypertension: A Randomized Controlled Trial. J Hypertens. 2009 Jul 1;22(7):792-801. doi: 10.1038/ajh.2009.63
  21. Furberg C.D. Renin Test-Guided Drug Treatment of Hypertension: The Need For Clinical Trials. Am J Hypertens. 2011;24(11):1158-63. doi: 10.1038/ajh.2011.170
  22. Garg J.P, Elliott W.J, Folker A, Izhar M, Black H.R. Resistant hypertension revisited: a comparison of two university - based cohorts. Am J Hypertens. 2005;18:619-26. doi: 10.1016/j.amjhyper.2004.11.021
  23. Calhoun D. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006;1:1039-45. doi: 10.2215/CJN.01060306
  24. Minutolo R, De Nicola L, Zamboli P, et al. Management of hypertension in patients with CKD: Differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46:18-25. doi: 10.1053/ j.ajkd.2005.03.019
  25. De Nicola L, Minutolo R, Chiodini P, et al. Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int. 2006;69:538-45. doi: 10.1038/sj.ki.5000085
  26. The African American Study of Kidney Disease and Hypertension Group (AASK). Successful blood pressure control in the African American study of kidney disease and hypertension. Arch Intern Med. 2002;162:1636-43. doi: 10.1001/archinte.162.14.1636
  27. Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9. doi: 10.1056/NEJMoa011161
  28. Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin - angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012 Aug;30(8):1656-64. doi: 10.1097/HJH.0b013e 3283551e98
  29. Václavík J, Sedlák R, Jarkovský J, Kociánová E, Táborský M. Effect of spironolactone in resistant arterial hypertension: a randomized, double - blind, placebo - controlled trial (ASPIRANT-EXT). Medicine (Baltimore). 2014 Dec;93(27):e162. doi: 10.1097/MD.0000000000000162
  30. Williams B, Mac Donald T.M, Caulfield M, Cruickshank J.K, Mc Innes G, Sever P, Webb D.J, Salsbury J, Morant S, Ford I, Brown M.J. Prevention And Treatment of Hypertension With Algorithm - based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug - resistant hypertension. BMJ Open. 2015 Aug 7;5(8):e008951. doi: 10.1136/bmjopen-2015-008951
  31. Williams B, Mac Donald T.M, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug - resistant hypertension (PATHWAY-2): a randomised, double - blind, crossover trial. Lancet. 2015;386(10008):2059-68. doi: 10.1016/ S0140-6736(15)00257-3

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies